



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 17, 2025

PTAS

MR. XIANGJING ZHAN
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

508975772

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/16/2025

REEL/FRAME: 069903/0654
NUMBER OF PAGES: 10

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-109326 (P38040)

ASSIGNOR:
KIKUCHI, SHOTA

DOC DATE: 06/05/2023

ASSIGNOR:
LAM, BETTY

DOC DATE: 06/05/2023

ASSIGNOR:
GREEN, JASON

DOC DATE: 06/02/2023

ASSIGNOR:
ROGNESS, DON

DOC DATE: 06/06/2023

ASSIGNOR:
WEINSTEIN, DAVID

DOC DATE: 06/05/2023

ASSIGNOR:
BURGESS, LARRY

DOC DATE: 06/22/2023

ASSIGNOR:
MALMSTROM, ROBERT

DOC DATE: 06/24/2023

ASSIGNOR:
HORNING, BENJAMIN

DOC DATE: 06/05/2023

ASSIGNOR:
LAMB, KELSEY

DOC DATE: 06/05/2023

ASSIGNOR:
OWYANG, ZACHARY

DOC DATE: 06/22/2023

ASSIGNEE:
VIVIDION THERAPEUTICS, INC.
5820 NANCY RIDGE DRIVE
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER: 63367781

FILING DATE: 07/06/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

Docket Number 48054-738.101

The undersigned:

- | | | | |
|--|--|---|--------------------------------------|
| 1. Shota Kikuchi
San Diego, CA (US) | 2. Betty Lam
San Diego, CA (US) | 3. Jason Green
San Diego, CA (US) | 4. Don Rogness
San Diego, CA (US) |
| 5. David Weinstein
San Diego, CA (US) | 6. Larry Burgess
San Diego, CA (US) | 7. Benjamin Horning
San Diego, CA (US) | 8. Kelsey Lamb
San Diego, CA (US) |
| 9. Zach Owyang
San Diego, CA (US) | 10. Robert Malmstrom
San Diego, CA (US) | | |

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Vividion Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS

for which application serial number 63/367,781 was filed on July 6, 2022 in the United States Patent and Trademark Office

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.


3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


PATENT ASSIGNMENT		Docket Number 48054-738.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: _____	_____ Shota Kikuchi's Signature	
Date: _____	_____ Betty Lam's Signature	
Date: _____	_____ Jason Green's Signature	
Date: _____	_____ Don Rogness's Signature	
Date: _____	_____ David Weinstein's Signature	
Date: <u>6-22-2023</u>	 Larry Burgess's Signature	
Date: _____	_____ Benjamin Horning's Signature	
Date: _____	_____ Kelsey Lamb's Signature	
Date: _____	_____ Zach Owyang's Signature	
Date: _____	_____ Robert Malmstrom's Signature	
RECEIVED AND AGREED TO BY ASSIGNEE: Vividion Therapeutics, Inc.		
Date: <u>06/29/2023</u>	Signature:  Name: Aleksandra Rizo Title: Chief Executive Officer	

PATENT ASSIGNMENT		Docket Number 48054-738.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: _____	_____ Shota Kikuchi's Signature	
Date: _____	_____ Betty Lam's Signature	
Date: _____	_____ Jason Green's Signature	
Date: _____	_____ Don Rogness's Signature	
Date: _____	_____ David Weinstein's Signature	
Date: _____	_____ Larry Burgess's Signature	
Date: _____	_____ Benjamin Horning's Signature	
Date: _____	_____ Kelsey Lamb's Signature	
Date: _____	_____ Zach Owyang's Signature	
Date: <u>24 Jul 2023</u>	<u></u> Robert Malmstrom's Signature	
RECEIVED AND AGREED TO BY ASSIGNEE: Vividion Therapeutics, Inc.		
Date: <u>06/29/2023</u>	Signature: <u></u>	
	Name: Aleksandra Rizo	
	Title: Chief Executive Officer	

PATENT ASSIGNMENT

Docket Number 48054-738.101

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 6/5/23 
Shota Kikuchi's SignatureDate: 6/5/23 
Betty Lam's SignatureDate: _____
Jason Green's SignatureDate: 6/6/23 
Don Rogness's SignatureDate: 6/5/23 
David Weinstein's SignatureDate: _____
Larry Burgess's SignatureDate: 6/5/23 
Benjamin Horning's SignatureDate: 6/5/23 
Kelsey Lamb's SignatureDate: _____
Zach Owyang's SignatureDate: _____
Robert Malmstrom's Signature

RECEIVED AND AGREED TO BY ASSIGNEE:

Vividion Therapeutics, Inc.

Date: 06/29/2023 Signature: 
Name: Aleksandra Rizo
Title: Chief Executive Officer

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California

County of San Diego }

On June 5+6, 2023 before me, Alexis McWilliams,
Date Here Insert Name and Title of the Officer

personally appeared Shota Kikuchi, Benjamin Horning, Betty Lam
Name(s) of Signer(s)
Kelsey Lamb, David Weinstein, Don Rogness

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature [Signature]
Signature of Notary Public

Place Notary Seal and/or Stamp Above

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: Patent Assignment

Document Date: July 6, 2022 Number of Pages: 2

Signer(s) Other Than Named Above: none

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian of Conservator

☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian of Conservator

☐ Other: _____

Signer is Representing: _____

PATENT ASSIGNMENT

Docket Number 48054-738.101

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Shota Kikuchi's Signature

Date: _____
Betty Lam's Signature

Date: 6-2-23
Jason Green's Signature

Date: _____
Don Rogness's Signature

Date: _____
David Weinstein's Signature

Date: _____
Larry Burgess's Signature

Date: _____
Benjamin Horning's Signature

Date: _____
Kelsey Lamb's Signature

Date: _____
Zach Owyang's Signature

Date: _____
Robert Malmstrom's Signature

State of Ohio
County of Hamilton



MISTY PIEPER-COMARATA
Notary Public, State of Ohio
My Commission Expires 07-29-2023
2018-RE-736489

Misty Pieper Comarata
06/02/2023

RECEIVED AND AGREED TO BY ASSIGNEE:

Vividion Therapeutics, Inc.

Date: 06/29/2023 Signature: Aleksandra Rizo
Name: Aleksandra Rizo
Title: Chief Executive Officer

PATENT ASSIGNMENT				Docket Number 48054-738.101
The undersigned:				
1. Shota Kikuchi San Diego, CA (US)	2. Betty Lam San Diego, CA (US)	3. Jason Green San Diego, CA (US)	4. Don Rogness San Diego, CA (US)	
5. David Weinstein San Diego, CA (US)	6. Larry Burgess San Diego, CA (US)	7. Benjamin Horning San Diego, CA (US)	8. Kelsey Lamb San Diego, CA (US)	
Zachary Owyang <i>et al.</i> 11/21/23				
9. ~~Zach~~ Owyang San Diego, CA (US)	10. Robert Malmstrom San Diego, CA (US)			
(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Vividion Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 5820 Nancy Ridge Drive, San Diego, CA 92121, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment. NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee: 1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s): PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS for which application serial number 63/367,781 was filed on July 6, 2022 in the United States Patent and Trademark Office (the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise). 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents. 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee. 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns. 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith. 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns. 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.				

PATENT ASSIGNMENT	Docket Number 48054-738.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:	
Date: _____	_____ Shota Kikuchi's Signature
Date: _____	_____ Betty Lam's Signature
Date: _____	_____ Jason Green's Signature
Date: _____	_____ Don Rogness's Signature
Date: _____	_____ David Weinstein's Signature
Date: _____	_____ Larry Burgess's Signature
Date: _____	_____ Benjamin Horning's Signature
Date: _____	_____ Kelsey Lamb's Signature
Date: 6/22/23	<u>Zachary Owyang</u> ~~Zach Owyang's Signature~~
	Zachary Owyang 2.0. 11/21/23
Date: _____	_____ Robert Malmstrom's Signature
RECEIVED AND AGREED TO BY ASSIGNEE: Vividion Therapeutics, Inc. Date: <u>06/29/2023</u> Signature: <u>Aleksandra Rizo</u> Name: Aleksandra Rizo Title: Chief Executive Officer	